[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pediatrics\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pediatrics":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,36,0,25,[9,50,77,123,150,180,220,244,272,303,324,345,365,388,416,440,466,493,517,549,574,605,632,657,682],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100361428","reproductive-axis-maturation-in-the-early-post-menarchal-years-100361428",false,"NCT03986021","Reproductive Axis Maturation in the Early Post-Menarchal Years","Reproductive Axis Maturation in the Early Post-Menarchal Years: A Pilot Study","* Part 1 - Pre-menarche monitoring (\"holding pattern\"):\n\nInclusion Criteria:\n\n* Age 8-14.5 years old\n* Healthy weight, defined as having a body weight \\>85% of expected (EBW) and a body mass index (BMI) \\\u003C99th percentile\n* Some breast development\n* Pre-menarche\n\nExclusion Criteria:\n\n* Taking or planning to take medications that affect reproductive hormones in the next 2 to 3 years (e.g. birth control pills, biotin supplements).\n* Planning to move more than 60 miles from the CRU within the next 2 to 3 years\n* Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.\n* First-degree relative with polycystic ovarian syndrome, premature ovarian insufficiency, hypogonadotropic hypogonadism, or other pubertal development disorder\n* Excessive exercise (defined as running \\>20 miles per week or its equivalent)\n* Pregnancy\n\nPart 2 - Post-menarche cycle tracking:\n\nInclusion Criteria:\n\n* Age at menarche 10-14.5 years old\n* Healthy weight, defined as having a body weight \\>85% of expected (EBW) and a body mass index (BMI) \\\u003C99th percentile\n* Approximately \\\u003C 6 months post-menarchal (will typically have completed 4 or fewer menstrual cycles)\n* Biochemical criteria: normal thyroid hormone, prolactin, and testosterone levels\n\nExclusion Criteria:\n\n* Taking or planning to take medications that affect reproductive hormones in the next 2 to 3 years (e.g. birth control pills, biotin supplements).\n* Planning to move more than 60 miles from the CRU within the next 2 to 3 years\n* Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.\n* First-degree relative with polycystic ovarian syndrome, premature ovarian insufficiency, hypogonadotropic hypogonadism, or other pubertal development disorder\n* Excessive exercise (defined as running \\>20 miles per week or its equivalent)\n* Anemia (defined as hemoglobin \\\u003C12.0 g\u002Fdl)\n\n  --Participants with hemoglobin between 11.5 g\u002Fdl and 12.0 g\u002Fdl may still participate by providing dried blood spots, or no more than 18 ml of blood during any given interval.\n* Pregnancy\n\nPart 3 - Intensive monitoring of ovarian follicle growth\n\nInclusion Criteria:\n\n* Age at menarche 10-14.5 years old\n* Healthy weight, defined as having a body weight \\>85% of expected (EBW) and a body mass index (BMI) \\\u003C99th percentile\n* Within 1 year of menarche\n* Biochemical criteria: normal thyroid hormone, prolactin, and testosterone levels\n\nExclusion Criteria:\n\n* Taking or planning to take medications that affect reproductive hormones in the next 1-2 years (e.g. birth control pills, biotin supplements).\n* Planning to move more than 60 miles from the CRU within the next year\n* Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.\n* First-degree relative with polycystic ovarian syndrome, premature ovarian insufficiency, hypogonadotropic hypogonadism, or other pubertal development disorder\n* Excessive exercise (defined as running \\>20 miles per week or its equivalent)\n* Anemia (defined as hemoglobin \\\u003C12.0 g\u002Fdl)\n\n  --Participants with hemoglobin between 11.5 g\u002Fdl and 12.0 g\u002Fdl may still participate by providing dried blood spots, or no more than 18 ml of blood during any given interval.\n* Pregnancy\n\nPart 4 - Late Post-menarche cycle tracking:\n\nInclusion Criteria:\n\n* Age 11-17.5 years old\n* Approximately 2-5 years post-menarchal\n* Biochemical criteria: normal thyroid hormone and prolactin\n\nExclusion Criteria:\n\n* Taking or planning to take medications that affect reproductive hormones in the next 2 to 3 years (e.g. birth control pills, biotin supplements).\n* Planning to move more than 60 miles from the CRU within the next 6 months\n* Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.\n* Anemia (defined as hemoglobin \\\u003C12.0 g\u002Fdl)\n\n  --Participants with hemoglobin between 11.5 g\u002Fdl and 12.0 g\u002Fdl may still participate by providing dried blood spots, or no more than 18 ml of blood during any given interval.\n* Pregnancy\n\nAdolescent girls, at-risk daughters, or sisters of women with PCOS\n\nThe girls with mothers or sisters with PCOS group will complete the Screening Visit and Parts 1-3. The same inclusion and exclusion criteria apply for Parts 1, 2, and 3 as stated above except that these individuals must have a first-degree relative with PCOS and they can have high androgen levels, excess body hair, and severe acne at screening.\n\nWomen with known PCOS (activities for 8 weeks only)\n\nInclusion Criteria:\n\n* Age \\>=18-34 years old\n* PCOS diagnosis\n* at least 3-years post-menarchal with irregular menstrual cycles\n* Biochemical (blood) or clinical signs of high androgen levels\n\nExclusion Criteria:\n\n* Cannot be taking any medications that affect reproductive or metabolic hormones (e.g. birth control pill, biotin supplements, spironolactone, metformin).\n* Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.\n* Pregnancy\n\nHealthy control women (Activities x 2 menstrual cycles)\n\nInclusion Criteria:\n\n* Age \\>=18-34 years old\n* at least 3-years post-menarchal with regular menstrual cycles every 21-35 days\n\nExclusion Criteria:\n\n* Cannot be taking any medications that affect reproductive or metabolic hormones (e.g. birth control pill, biotin supplements, spironolactone, metformin).\n* Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.\n* PCOS diagnosis or first-degree relative with disorder\n* Pregnancy\n\nMothers of pediatric participants (Activities for 8 weeks \u002F 2 menstrual cycles)\n\nInclusion Criteria:\n\n* Age \\>=18-65 years old\n* Biological mother of A Girl's First Period participant\n\nExclusion Criteria:\n\n* Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.\n* Pregnancy",true,"FEMALE","8 Years","65 Years",{"count":22,"type":23},400,"ESTIMATED","OBSERVATIONAL","Background:\n\nMost adult women with irregular periods of unknown cause report symptoms dating back to early adolescence. This study aims to learn how girls' periods change in the 2 years after their first period. We are also looking at girls who may have a condition called PCOS. This will help researchers learn what healthy puberty looks like and how they can spot signs of hormone problems early on.\n\nObjective:\n\nTo learn how long it takes girls to develop regular menstrual cycles after their first period.\n\nEligibility:\n\nHealthy girls ages 8-14 who either (1) haven't had their first period but show signs of puberty, such as breast development and hair in the genital area; or (2) had their first period in the past 6 months\n\nGirls at risk for PCOS age 8-14 who have a mom or sister with PCOS\n\nGirls with irregular menstrual cycles age 11-17.5\n\nTo compare with the girls, we are looking at women \\>=18-34 years old with PCOS,\n\nHealthy women \\>= 18-34 years old without PCOS,\n\nand Mothers of pediatric participants age 18-65\n\nDesign:\n\nBoth parents or guardians must allow their daughter to participate. They must attend all study visits with her.\n\nParticipants will first be screened by phone. Those who qualify will be screened in person. They will have a physical exam. They will give blood and urine samples. They will have an ultrasound of their abdomen. They will fill out questionnaires. They will sit in a BOD POD for 6 minutes: This is an egg- shaped machine that takes body measurements. They have the option to provide DNA samples.\n\nParticipants will have sets of visits at home or at the clinic about every 6 months. The number of visits in each set will depend on their menstrual cycle. Then they will have a final visit. Visits will include repeats of the screening tests. There are additional parts that participants may choose to be involved in depending on how involved they want to be.\n\nAt home, participants will collect their urine daily to measure hormones. They will keep a diary of their periods.\n\nAdults: Women with known PCOS will complete the same Screening Visit as the girls and will collect dried urine specimens at home for 8 weeks;\n\nThe Healthy control women group will complete the same Screening Visit as the girls and collect dried urine specimens at home for 2 menstrual cycles;\n\nThe Mothers of pediatric participants group will complete a Screening Visit (informed consent, urine pregnancy test) and collect vaginal swab specimens at home for 2 menstrual cycles (approx. 8 weeks)....",[27,28,29,30],"Reproductive Physiological Processes","Pediatrics","Adolescent Health","Adolescent Development",[32,33,34,35,36],"Menarche","Adolescent","Physiology","Hormones","Natural History","RECRUITING","2026-07-01",{"date":40,"type":41},"2026-07-02","ACTUAL",{"date":43,"type":41},"2019-12-19",{"date":45,"type":23},"2029-07-01",{"name":47,"class":48},"National Institute of Environmental Health Sciences (NIEHS)","NIH",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":49},"100644743","postoperative-pain-after-pediatric-adenotonsillectomy-with-ketorolac-or-ibuprofen-100644743","NCT07672418","Postoperative Pain After Pediatric Adenotonsillectomy With Ketorolac or Ibuprofen","Assessment of Postoperative Pain Outcomes Following Pediatric Adenotonsillectomy and the Impact on Non-Steroidal Anti-Inflammatory Drugs","Inclusion Criteria:\n\nScheduled for outpatient adenotonsillectomy Age 13-18 years ASA physical status I-III Patient or parent has access to a phone with text-messaging capability Patient assent Parent or legal guardian consent\n\nExclusion Criteria:\n\nInpatient admission or planned 23-hour observation Known hematologic condition or prior bleeding disorder Current anticoagulant use Known or suspected chronic kidney disease or solitary kidney Known or suspected liver disease or prior liver transplant Known or suspected mitochondrial disease or genetic anomaly Inability to self-report pain History of gastrointestinal ulcer or bleeding Allergy to acetaminophen, ibuprofen, or ketorolac Non-English or non-Spanish speaking Chronic pain or condition requiring frequent routine NSAID use Patient refusal Parent or guardian refusal","ALL","13 Years","18 Years",{"count":61,"type":23},200,"This prospective observational study will evaluate postoperative pain after outpatient pediatric adenotonsillectomy in adolescents prescribed either acetaminophen with ibuprofen or acetaminophen with oral ketorolac after discharge, based on the prescribing preference of the otolaryngology surgeon. Participants will complete text-message surveys after discharge to assess pain severity, medication administration, and functional recovery for up to 14 days.",[64,28,65],"Sleep","Adenotonsillectomy","NOT_YET_RECRUITING","2026-06-23",{"date":69,"type":41},"2026-06-29",{"date":71,"type":23},"2026-06-24",{"date":73,"type":23},"2027-06-30",{"name":75,"class":76},"Baylor College of Medicine","OTHER",{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":12,"sex":57,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":97,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":122},"100580300","phase-3-morphine-or-ketamine-for-analgesia-100580300","NCT06835504","Morphine or Ketamine for Analgesia","Efficacy of Intravenous Sub-Dissociative Ketamine Versus Intravenous Morphine in Children With Acute Pain","MoKA","Inclusion Criteria:\n\n1. Abdominal pain or isolated long-bone extremity fracture (suspected or proven)\n2. Self-reported pain score of ≥ 6\u002F10\n3. Requires IV morphine for analgesia as determined by the treating physician\n\nExclusion Criteria:\n\n1. Weight \\> 82.4 kg\n2. Known allergy\u002Fcontraindication to morphine or ketamine\n3. Antecedent receipt of ketamine related to presenting complaint\n4. Inability to use self-report measures of pain or questionnaires\n5. Chronic disease associated with pain\n6. Chronic pain condition requiring use of opioids as outpatient\n7. Hemodynamic instability or critical illness per treating physician\n8. Altered mental state (e.g., GCS , 14 or clinical intoxication)\n9. Known history of schizophrenia, liver or kidney problems, or osteogenesis imperfecta\n10. Concern for open fracture, neurovascular compromise, or compartment syndrome\n11. Injuries in addition to the extremity injury (e.g., head, neck, abdomen)\n12. Known or reported pregnancy\n13. Does not speak English or Spanish\n14. Patient previously enrolled in this study\n15. Wards of state, foster children, or children in custody","6 Years","17 Years",{"count":88,"type":23},1010,"INTERVENTIONAL",[91],"PHASE3","Pain is common in children presenting to the emergency department but is frequently undertreated, leading to both short- and long-term consequences. Morphine is the standard treatment for children with moderate to severe acute pain, but its use is associated with serious side effects and caregiver and clinician concerns related to opioid administration. The investigators aim to determine if sub-dissociative ketamine is non-inferior to morphine for treating acute pain and a preferable alternative for treating acute pain in children because of its more favorable side effect profile and potential long-term benefits related to pain-related function, analgesic use\u002Fmisuse, and mental and behavioral health outcomes.",[94,95,96,28],"Abdominal Pain","Isolated Extremity Fracture","Pain",[98,99,100,101,102,103,104,105,106,107,108,109,110,111,112],"Ketamine","Morphine","Pediatric","Children","Sub-dissociative","Opioid-sparing","Emergency medicine","Emergency care","Emergency department","Post-traumatic stress","Anxiety","Depression","Abdominal pain","Fracture","Analgesia","2026-06-08",{"date":115,"type":41},"2026-06-09",{"date":117,"type":23},"2026-09-01",{"date":119,"type":23},"2030-02-28",{"name":121,"class":76},"Columbia University",8,{"id":124,"slug":125,"hasResults":12,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":12,"sex":57,"minAge":85,"maxAge":86,"enrollmentInfo":131,"targetDuration":4,"studyType":89,"phases":133,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":49},"100534153","phase-1-safety-and-feasibility-of-intraoperative-visualization-with-cytalux-in-children-100534153","NCT06235125","Safety and Feasibility of Intraoperative Visualization With Cytalux in Children","A Pilot Study of Near-Infrared Imaging Using the Novel Imaging Agent Cytalux for Adolescent Patients With Metastatic Osteosarcoma Undergoing Pulmonary Metastasectomy","Cytalux","Inclusion Criteria:\n\n1. Patients 6-17 years of age at the time of study enrollment\n2. Willingness of research participant or legal guardian\u002Frepresentative to give written informed consent\n3. Willingness of patients (subjects) age 12-17 to provide written adolescent assent\n4. Patient weight greater than or equal to 20 kg\n5. Histologically confirmed diagnosis of osteosarcoma, synovial sarcoma, hepatoblastoma, rhabdomyosarcoma, Ewing sarcoma, Wilms tumor or other non-rhabdomyosarcoma soft tissue sarcoma\n6. Imaging findings highly suspicious for pulmonary metastatic disease based on CT, PET-CT or other imaging and warranting pulmonary surgery based on the judgment of the treating team. At least one nodule ≥4mm measured by preoperative imaging.\n7. Female (assigned female at birth) participant is not pregnant and agrees to an acceptable form of contraception from the time of consent through 30 days after study intervention. Confirmed abstinence is an acceptable form of contraception.\n8. Female (assigned female at birth) participant must agree to not donate ova from time of consent until 30 days after study intervention\n9. Male (assigned male at birth) participant must agree to not donate sperm from time of consent until 30 days after study intervention.\n\nExclusion Criteria:\n\n1. Any medical condition that in the opinion of the investigators could potentially jeopardize the safety of the subject\n2. History of anaphylactic reactions to products containing indocyanine green for near infrared imaging. Subjects with a medical history of 'idiopathic anaphylaxis' will also be excluded.\n3. History of allergy to any of the components of CYTALUX™ (PAFOLACIANINE) INJECTION\n4. Presence of any psychological, familial, sociological condition or geographical challenges potentially hampering compliance with the study protocol or follow-up schedule\n5. Impaired renal function defined as eGFR\\\u003C 50 mL\u002Fmin\u002F1.73m2\n6. Impaired liver function defined as values \\> 3x the upper limit of normal (ULN) for alanine aminotransferase (ALT) or aspartate aminotransferase (AST), alkaline phosphatase (ALP), or \\>2x ULN for total bilirubin except in subjects with Gilbert's syndrome.\n7. Patient unable or unwilling to discontinue folate, folic acid, or folate-containing supplements 48 hours before study drug administration\n8. History of drug-related serious adverse event with prior Cytalux administration will be an exclusion for re-enrollment for contralateral surgery (see section 5.7).\n9. Participants will be excluded if their 12th or 18th birthday would occur during study participation\n10. Male sex at birth and commitment to acceptable form of contraception from time of consent through 30 days after study intervention with confirmed abstinence as an acceptable form of contraception as an inclusion criterion.",{"count":132,"type":23},10,[134],"PHASE1","Pediatric subjects aged 6-17 with biopsy confirmed cancer and imaging findings suspicious for pulmonary metastatic disease scheduled to undergo pulmonary metastasectomy via and open or minimally invasive approach.",[137,138,139,140,28],"Osteosarcoma","Pulmonary Metastasis","Fluorescence","Metastatic Sarcoma","2026-06-03",{"date":143,"type":41},"2026-06-05",{"date":145,"type":41},"2024-04-08",{"date":147,"type":23},"2026-08-31",{"name":149,"class":76},"Ann & Robert H Lurie Children's Hospital of Chicago",{"id":151,"slug":152,"hasResults":12,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":12,"sex":57,"minAge":158,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":89,"phases":162,"briefSummary":164,"conditions":165,"keywords":168,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":49},"100601793","effectiveness-of-high-energy-density-enteral-nutrition-for-enhancing-physical-growth-and-cognitive-brain-development-in-infants-with-congenital-heart-disease-100601793","NCT07115108","Effectiveness of High-Energy Density Enteral Nutrition for Enhancing Physical Growth and Cognitive Brain Development in Infants With Congenital Heart Disease","Effectiveness of High-Energy Density Enteral Nutrition for Enhancing Physical Growth and Cognitive Brain Development in Infants With Congenital Heart Disease: A Randomized Controlled Study","RCT","Inclusion Criteria:\n\n* Diagnosed with congenital heart disease through symptoms, physical signs, imaging, and ultrasound examinations.\n* Age 0-6 months\n* Children with nutritional risks (defined by STRONGkids: Nutritional risk screening tool for children )\n* Artificial or mixed feeding\n* Open heart surgery under cardiopulmonary bypass\n* The guardians of the children voluntarily participate in this study and sign a written informed consent form before the surgery.\n\nExclusion Criteria:\n\n* Diagnosed with major non cardiac diseases leading to nutritional intake disorders, such as congenital gastrointestinal malformations, preoperative diagnosis of gastroesophageal reflux, genetic diseases related to growth restriction, and various syndromes with chromosomal abnormalities (trisomy 21 syndrome, trisomy 18 syndrome)\n* Abnormal immune system function due to congenital or acquired factors, unable to effectively resist pathogens or eliminate abnormal cells, which can be divided into primary and secondary immunodeficiencies.\n* Any pre - operative history of neurological diseases (e.g., encephalitis, epilepsy).\n* Secondary or primary gastrointestinal infection symptoms such as abdominal distension and diarrhea after surgery.\n* Estimated stay time in the postoperative intensive care unit ≤ 2 days","0 Months","6 Months",{"count":161,"type":23},160,[163],"NA","The purpose of this study is to compare the effect of high and ordinary energy density enteral nutrition for improving physical growth and brain cognitive development in infants with congenital heart disease after operation, as well as evaluate the safety of interventions.",[166,167,28],"Congenital Heart Disease","Enteral Nutrition",[169,170,28],"Congenital heart disease","Enteral nutrition","2026-05-12",{"date":173,"type":41},"2026-05-13",{"date":175,"type":41},"2025-10-13",{"date":177,"type":23},"2026-12-31",{"name":179,"class":76},"Children's Hospital of Fudan University",{"id":181,"slug":182,"hasResults":12,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":12,"sex":57,"minAge":159,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":89,"phases":190,"briefSummary":191,"conditions":192,"keywords":197,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":219},"100377988","effect-of-giving-reduced-fluid-in-children-after-trauma-100377988","NCT04201704","Effect of Giving Reduced Fluid in Children After Trauma","Effect of Restricted Fluid Management Strategy on Outcomes in Critically Ill Pediatric Trauma Patients: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Trauma patients older than 6 months and younger than 15 years admitted to the pediatric intensive care unit (PICU)\n* Patients admitted to the PICU directly from the Emergency Department (ED)\n* Patients admitted to the PICU from the operating room (OR)\n* Patients transferred to PICU from outside facility ED (need to have been in ED 12 hours or less)\n\nExclusion Criteria:\n\n* Patients transferred to PICU from outside PICU or inpatient floor\n* Patients transferred to PICU from outside facility ED if \\>12 hours\n* Patients expected to be discharged from the PICU within 24 hours\n* Patient with congenital heart disease as defined by a congenital cardiac defect requiring surgery or medication\n* Patient with diagnosis of chronic cardiac condition (e.g. hypertension, cardiac arrhythmia)\n* Patients with chronic kidney disease as defined by an abnormality of kidney structure or function, present for more than 3 months, with implications to health\n* Post-operative transplant, cardiac, and neurosurgical patients\n* Patients with traumatic brain injury\n* Patients with any disease that may affect baseline blood pressure and heart rate (endocrine disorders, certain genetic disorders, mitochondrial diseases)\n* Hypotension requiring vasopressor therapy\n* If massive transfusion protocol initiated","15 Years",{"count":189,"type":23},250,[163],"This study is designed to help decide how much intravenous (IV) fluid should be given to pediatric trauma patients. No standard currently exists for managing fluids in critically ill pediatric trauma patients, and many fluid strategies are now in practice. For decades, trauma patients got high volumes of IV fluid. Recent studies in adults show that patients actually do better by giving less fluid. The investigators do not know if this is true in children and this study is designed to answer that question and provide guidelines for IV fluid management in children after trauma.",[193,28,194,195,196],"Critical Illness","General Surgery","Fluid Therapy","Wounds and Injuries",[195,198,199,196,200,201,202,203,204,205,206,207,208,209,210],"Intensive Care Units, Pediatric","Critical Care","Multiple Trauma","Treatment Outcome","Postoperative Complications","Resuscitation","Hemodynamics","Infusions, Intravenous","Isotonic Solutions","Crystalloid Solutions","Diuretics","Organism Hydration Status","Body Water","2026-05-04",{"date":213,"type":41},"2026-05-07",{"date":215,"type":41},"2018-08-27",{"date":217,"type":23},"2027-09",{"name":121,"class":76},4,{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":12,"sex":57,"minAge":159,"maxAge":86,"enrollmentInfo":227,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":229,"conditions":230,"keywords":233,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":242,"locationsCount":49},"100628202","vibandz-feasibility-study-100628202","NCT07458568","ViBandz Feasibility Study","ViBandz Feasibility Study in the Neurological Pediatric Population","Inclusion Criteria (Children):\n\n* Children of ages 6 months to 17 years old\n* Neurologic conditions resulting in abnormal movement of at least one extremity\n* Appointment scheduled in CM PT\u002FOT clinic that would include targeted focal vibration as a standard of care\n\nExclusion Criteria (Children):\n\n* Wards of the state\n\nInclusion Criteria (Parent\u002FLAR):\n\n* Parent or Legally Authorized Representative of a child with inclusion criteria above\n* English-speaking\n\nExclusion Criteria (Parent\u002FLAR):\n\n* Non-English speaking",{"count":228,"type":23},30,"This is a single site, mixed methods, feasibility study of the ViBandz device at a Midwest pediatric tertiary care hospital in a physical and occupational therapy clinic.",[28,231,232],"Neurologic Dysfunction","Vibration Therapy",[234,235],"pediatrics","vibration therapy","2026-04-22",{"date":238,"type":41},"2026-04-27",{"date":240,"type":41},"2026-04-07",{"date":177,"type":23},{"name":243,"class":76},"Children's Mercy Hospital Kansas City",{"id":245,"slug":246,"hasResults":12,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":12,"sex":57,"minAge":251,"maxAge":86,"enrollmentInfo":252,"targetDuration":4,"studyType":89,"phases":254,"briefSummary":255,"conditions":256,"keywords":259,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":49},"100634116","food-is-medicine-in-pediatric-patients-with-diabetes-100634116","NCT07535502","Food is Medicine in Pediatric Patients With Diabetes","The Effect of a Novel Food is Medicine Program on Outcomes in Pediatric Patients With Diabetes: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Current patients of the UMMMC Pediatric Endocrinology Clinic\n* Children and Adolescents less than or equal to 17 years of age at the time of enrollment\n* Diagnosed with Type 1 Diabetes at least 3 months ago\n* Public (MassHealth or Medicaid) Health Insurance\n\nExclusion Criteria:\n\n* Celiac disease or severe gluten allergy\n* Congenital, genetic, or chronic comorbidities\n* DCF Custody\n* Pregnant women\n* Prisoners\n* Non-English speaking subjects","5 Years",{"count":253,"type":23},50,[163],"The objective of this randomized controlled trial is to evaluate the effect of novel Food is Medicine Programming in the form of medically tailored pre-packaged meals for pediatric patients with Type 1 Diabetes. The provision of medically-tailored meals to children and adolescents with diabetes that have potential food security or access concerns in addition to nutrition counseling will improve clinical outcomes, decrease healthcare utilization, and improve health-related quality of life (HRQOL). Consulting with a Registered Dietician is the established multidisciplinary standard of care for pediatric patients with diabetes at UMass. Community Servings provides a medically-tailored pre-packaged meal plan designed for pediatric patients with Type 1 Diabetes. The addition of Community Servings to the current standard of care in pediatric patients with potential food security or access concerns will further improve clinical, decrease healthcare utilization, and improve HRQOL outcomes in pediatric patients with Type 1 Diabetes.",[257,28,258],"Type I Diabetes","Food Insecurity",[260,257,28,258,261,262],"Food is Medicine","Continuous Glucose Monitoring","Medically-tailored Meals","2026-04-14",{"date":265,"type":41},"2026-04-17",{"date":267,"type":23},"2026-05-20",{"date":269,"type":23},"2029-12-31",{"name":271,"class":76},"University of Massachusetts, Worcester",{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":278,"eligibilityCriteria":279,"healthyVolunteers":12,"sex":57,"minAge":85,"maxAge":59,"enrollmentInfo":280,"targetDuration":4,"studyType":89,"phases":282,"briefSummary":283,"conditions":284,"keywords":289,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":302},"100604140","phase-3-topical-diclofenac-vsoral-ibuprofen-for-msk-pain-in-children-100604140","NCT07145645","Topical Diclofenac vs.Oral Ibuprofen for MSK Pain in Children","Topical Diclofenac vs. Oral Ibuprofen for Musculoskeletal Pain in Children: A Multi-centre, Randomized Pilot Feasibility Trial","TOP-MAP","Inclusion Criteria:\n\n1. Age 6 to 18 years old.\n2. Injury less than or equal to 4 days old\n3. Non-fractured MSK soft-tissue injury (ankle or knee, confirmed clinically and\u002For radiographically)\n4. Pain score of more than or equal to 3 on the verbal numerical rating scale, with movement in the past 2 hours or before analgesia\n5. Willing and able to complete follow-up surveys as per study protocol\n\nExclusion Criteria:\n\n1. Previous enrolment in the trial\n2. Barriers to topical treatment application, including skin conditions (e.g. eczema, infection, open wounds) or overlying material (e.g., rigid cast) which would make applying topical treatment impossible.\n3. Any other history, condition, therapy, or uncontrolled intercurrent illness, which could, in the opinion of the Qualified Medical Investigator or treating physician, would make the participant unsuitable for this study\n4. Any contraindication to NSAID use including but not limited to a history of GI bleeding, gastric ulcer, inflammatory bowel disease, prior cerebrovascular bleeding, bleeding diathesis, interstitial kidney disease\n5. Taking NSAIDs daily for other indications (e.g, chronic pain or arthritis)\n6. Known hypersensitivity to ibuprofen, diclofenac or other NSAIDs.\n7. Any known allergy or intolerance to any components or trace constituents (e.g., aloe vera, tree nuts or corn) of the investigational products\n8. Current use of prohibited medications known to impair renal function when combined with NSAIDs or cause potential additive risks of gastrointestinal toxicity and renal impairment\n9. Absence of a parent\u002Fguardian for children who are not mature minors.\n10. Caregiver and\u002For child cognitive impairment precluding the ability to complete study procedures\n11. Inability to obtain consent, and to complete follow-up surveys due to language barrier\n12. Known or suspected late pregnancy (gestational age ≥20 weeks) at the time of enrolment or breastfeeding females, due to the risk of premature closure of the ductus arteriosus associated with NSAID use\n13. Current enrollment in another pain-related clinical trial or in a study that, in the opinion of the Qualified Medical Investigator, may interfere with enrollment, involve investigational products that interact with study medications, or compromise follow-up and outcome assessment",{"count":281,"type":23},60,[91],"The TOP-MAP pilot trial has multiple goals. The first goal of this pilot clinical trial is to find out if it will be possible to carry out a study at multiple pediatric emergency department sites (Peds ED) comparing Non-Steroidal Anti-Inflammatory (NSAID) gel applied to a new ankle or knee injury to NSAIDs taken by mouth in kids aged 6-18. The investigators want to determine if the gel works as well or better at reducing pain than NSAIDs given by mouth. Based on studies done on adults, the investigators know that NSAIDs that are applied directly to an injury work as well at relieving pain as NSAIDs that are taken by mouth. Another goal of this pilot trial is to determine if it is possible to recruit participants to the study, and if the participants complete the questionnaire and take the medications as prescribed on Day 1.\n\nThe participants will be in the study for 14 days. Participants will be required to take the oral NSAID medication and to apply the topical NSAID gel 3 times a day for the first 3 days after their visit to the ED. The investigators will ask the participants to rate their pain on a scale of 0 (no pain) to 10 (worst pain ever) before and after they use the medicine. On day 7, the participants will rate their pain, and their activity level. On day 14 participants will do the same.",[285,28,286,287,288],"Musculoskeletal Injury","Sprain and Strain of Ankle","Sprain Knee","Strain Knee",[290,291,28,292,293],"Non Steroidal Anti-Inflammatory","Pediatric Emergency Department","Ankle or Knee Injury","Topical NSAIDs",{"date":295,"type":41},"2026-04-13",{"date":297,"type":41},"2026-04-02",{"date":299,"type":23},"2028-03-31",{"name":301,"class":76},"University of Calgary",2,{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":57,"minAge":4,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":312,"conditions":313,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":302},"100553096","asia-pediatric-intensive-care-epidemiology-and-outcomes-study-100553096","NCT06481644","Asia Pediatric Intensive Care Epidemiology and Outcomes Study","AsiaPedIC","Inclusion Criteria:\n\n* All patients admitted to the pediatric ICUs of participant hospitals\n\nExclusion Criteria:\n\n* No consent",{"count":311,"type":23},10000,"The overall objective of this study is to improve the standard of care of critically ill pediatric patients. The specific aims are to describe the clinical profile and outcomes of all admissions to Asian pediatric ICUs, determine the risk factors associated with poor outcomes, determine quality indicators for benchmarking ICU performance across sites and develop and train artificial intelligence algorithms to predict mortality, length of ICU stay and resource utilization.",[28,314,193],"Intensive Care Unit",{"date":316,"type":41},"2026-04-08",{"date":318,"type":41},"2024-08-01",{"date":320,"type":23},"2027-12-31",{"name":322,"class":323},"KK Women's and Children's Hospital","OTHER_GOV",{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":12,"sex":57,"minAge":251,"maxAge":330,"enrollmentInfo":331,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":333,"conditions":334,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":49},"100630647","growth-and-endocrinological-outcomes-in-patients-who-underwent-or-did-not-undergo-haematopoietic-stem-cell-transplantation-in-prepubertal-age-100630647","NCT07490392","Growth and Endocrinological Outcomes in Patients Who Underwent or Did Not Undergo Haematopoietic Stem Cell Transplantation in Prepubertal Age","Inclusion Criteria:\n\nPrepubertal HSCT Group - Pediatric Oncology Patients\n\n* HSCT performed for pediatric oncology between January 2005 and December 2020;\n* Pubertal development not yet initiated at the time of HSCT (testicular volume \\\u003C 4 ml bilaterally, uterine volume \\\u003C 2.5 ml).\n\nNon-HSCT Group - Pediatric Oncology Patients\n\n* Diagnosis of pediatric oncology between January 2005 and December 2020;\n* No HSCT performed before the onset of pubertal development (testicular volume \\\u003C 4 ml bilaterally, uterine volume \\\u003C 2.5 ml) during the same period.\n\nFor Both Groups\n\n* Received prepubertal chemotherapy including at least one of the following agents: cyclophosphamide, ifosfamide, procarbazine, cisplatin, carboplatin, melphalan, thiotepa, busulfan, treosulfan;\n* Spontaneous pubertal development with autonomous progression, without the need for exogenous hormone therapy (testosterone or estradiol);\n* Endocrinological follow-up to assess growth progression conducted until the end of pubertal development at the Endocrine-Metabolic Diseases Program, UOC Pediatrics, IRCCS AOUBo;\n* Obtain Informed consent.\n\nExclusion Criteria:\n\n* Delayed puberty (testicular volume \\\u003C 4 ml at age \\> 14 years or Tanner stage 2 breast development at age \\> 13 years) requiring exogenous hormone therapy with testosterone or estradiol;\n* For pediatric oncology patients not undergoing prepubertal HSCT, having received HSCT during pubertal development.","40 Years",{"count":332,"type":23},300,"This observational study evaluates growth and endocrine outcomes in pediatric oncology patients who underwent prepubertal HSCT compared to those who did not. The study focuses on final height, pubertal growth spurt, and sex hormone production, with data collected retrospectively and prospectively through standard clinical follow-up.",[335,28],"Hematopoietic Stem Cells Transplantation","2026-03-18",{"date":338,"type":41},"2026-03-24",{"date":340,"type":23},"2027-01-01",{"date":342,"type":23},"2036-02-13",{"name":344,"class":76},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":346,"slug":347,"hasResults":12,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":12,"sex":57,"minAge":4,"maxAge":352,"enrollmentInfo":353,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":362,"leadSponsor":364,"locationsCount":49},"100630144","reliability-and-validation-of-the-wb-mri-radiological-score-in-crmo-100630144","NCT07483853","Reliability and Validation of the WB-MRI Radiological Score in CRMO","Reliability and Validation of the WB-MRI Radiological Score in CRMO: Retrospective Observational Study in Paediatric Patients","Inclusion Criteria:\n\n* Patients with a diagnosis of CRMO according to the international Bristol clinical and radiologic criteria, followed at the Pediatric Rheumatology Clinic of the Pediatric Unit, IRCCS AOU Bologna, Sant'Orsola Hospital;\n* Age under 18 years at the time of CRMO diagnosis;\n* At least one WB-MRI performed as part of routine clinical follow-up between January 2015 and the start date of the study;\n* Availability of complete clinical documentation (including reports, radiologic images, and clinical information) sufficient to apply both the WB-MRI score and the PedCNO score;\n* Obtain informed consent.\n\nExclusion Criteria:\n\n\\- Alternative diagnoses accounting for the bone lesions (e.g., infections, neoplasms).","32 Years",{"count":354,"type":23},15,"This study evaluates the inter-observer reliability of a standardized WB-MRI scoring system for CRMO and its consistency with the PedCNO clinical score. It also investigates whether changes in the radiologic score mirror therapeutic response, supporting a more objective clinical-radiological disease assessment.",[357,28],"Chronic Recurrent Multifocal Osteomyelitis","2026-03-17",{"date":360,"type":41},"2026-03-19",{"date":340,"type":23},{"date":363,"type":23},"2027-07-01",{"name":344,"class":76},{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":12,"sex":57,"minAge":372,"maxAge":373,"enrollmentInfo":374,"targetDuration":4,"studyType":89,"phases":375,"briefSummary":376,"conditions":377,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":49},"100610240","tele-pcit-for-healthy-relationships-in-families-at-risk-100610240","NCT07225010","Tele-PCIT for Healthy Relationships in Families At-Risk","Fostering Healthy Relationships Through Tele-PCIT for Families of South Carolina","Inclusion Criteria:\n\n* Child participants must:\n\n  * Be between 2:0-6:11 years old\n  * Have elevated levels of disruptive behavior problems as defined by the Eyberg Child Behavior Inventory (ECBI)\n  * Have receptive language appropriate for PCIT (approximately 2-years old)\n  * Medicaid eligible, or be uninsured\n  * Score of 1 or greater on an ACEs (adverse childhood experiences) measure (PEARLS)\n* Parent participants must:\n\n  * Be the child's legal guardian\n  * Be able to provide consent for themselves (i.e., have decision making capacity and do not need a legally authorized representative themselves).\n  * Must be living with the child\n\nExclusion Criteria:\n\n* None","2 Years","7 Years",{"count":253,"type":23},[163],"The study will examine Parent Child Interaction Therapy (PCIT) delivered via telehealth (Tele-PCIT) for young children at risk for adverse childhood experiences and\u002For trauma exposure.",[378,28],"Disruptive Behavior","2026-03-05",{"date":381,"type":41},"2026-03-06",{"date":383,"type":41},"2026-02-12",{"date":385,"type":23},"2028-08",{"name":387,"class":76},"Medical University of South Carolina",{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":57,"minAge":159,"maxAge":59,"enrollmentInfo":395,"targetDuration":4,"studyType":89,"phases":397,"briefSummary":398,"conditions":399,"keywords":403,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":49},"100585463","timely-ordering-of-pharmacogenetic-testing-100585463","NCT06902688","Timely Ordering of Pharmacogenetic Testing","Timely Ordering of Pharmacogenetic Testing in Pediatric Oncology","Inclusion Criteria:\n\n* Inpatient at The Hospital for Sick Children\n* Between 6 months to 18 years old\n\nExclusion Criteria:\n\n* Prior pharmacogenetic testing and\u002For prior receipt of a targeted medication\n* Current Intensive Care Unit (ICU) admission\n* Expected hospital discharge is prior to midnight on the day of admission",{"count":396,"type":23},275,[163],"The goal of this trial is to learn if a machine learning (ML) model can help optimize drug therapy in the pediatric population. The main question\\[s\\] it aims to answer are whether a machine learning model predicting receipt of a targeted medication within the next three months:\n\n* Increases the offering of pharmacogenetic testing prior to receipt of a targeted medication\n* Increases the number of patients with pharmacogenetic results prior to receipt of a targeted medication\n* Increases the number of patients who have alteration in medication choice or dose based on pharmacogenetic results\n\nThis trial only focuses on the prediction and provision of participants with a high-risk of receiving a medication with a pharmacogenetic indication in the next three months.",[400,401,28,402],"Machine Learning","Prediction Models","Precision Medicine",[404,405,406,407,234],"precision medicine","machine learning","pharmacogenetics","prediction models","2026-03-03",{"date":379,"type":41},{"date":411,"type":41},"2025-06-10",{"date":413,"type":23},"2027-06-10",{"name":415,"class":76},"The Hospital for Sick Children",{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":422,"eligibilityCriteria":423,"healthyVolunteers":12,"sex":57,"minAge":424,"maxAge":425,"enrollmentInfo":426,"targetDuration":4,"studyType":89,"phases":428,"briefSummary":429,"conditions":430,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":436,"leadSponsor":438,"locationsCount":4},"100619874","evaluation-of-the-diagnostic-capabilities-of-saliva-samples-from-pediatric-patients-promoting-active-involvement-of-the-individuals-concerned-and-their-families-100619874","NCT07350291","Evaluation of the Diagnostic Capabilities of Saliva Samples From Pediatric Patients, Promoting Active Involvement of the Individuals Concerned and Their Families.","Evaluation of the Diagnostic Capabilities of Saliva Samples From Pediatric Patients, Promoting Active Involvement of the Individuals Concerned and Their Families: Protocol for a Randomized Intra-individual Study.","Presap","Inclusion Criteria:\n\n* Infants aged between 28 days and under 24 months.\n\n  * Admission to paediatric A\\&E or general paediatrics.\n  * Respiratory conditions requiring treatment for microbiological diagnosis by upper airway sampling.\n  * Collection of consent signed by legal representatives or guardians with parental authority. Except in cases where there is a single parent with parental authority.\n  * Persons affiliated with or beneficiaries of a social security scheme.\n\nExclusion Criteria:• Refusal to participate by one of the legal representatives or the patient.\n\n* Patients with a contraindication to ASNA (those with haemophilia, on anticoagulants or with thrombocytopenia).\n* Patients with a known increased risk of epistaxis (nosebleeds), hypertrophic rhinitis or other conditions causing excessive mucosal fragility.\n* Participation in another study that would impact the primary objective of this research.\n* Patients who may be allergic to the material used in the sponge pacifier.\n* Patients in a life-threatening emergency situation.","28 Days","23 Months",{"count":427,"type":23},502,[163],"The management of respiratory infections accounts for a large proportion of winter activity in paediatric wards. The main pathologies are bronchiolitis, affecting infants under the age of 2. Today, the reference method for diagnosing respiratory pathogen infections is nasopharyngeal aspirate (NPA), performed by paramedical staff. However, this technique is invasive and traumatic for paediatric patients. During the SARS-CoV-2 pandemic, salivary sampling was used on a large scale in the paediatric population, and showed good concordance with reference samples, as well as better tolerance\u002Facceptability. The aim of the PreSaP (Paediatric Saliva Sampling) study is to assess the diagnostic capabilities of saliva samples¹ . This will be a monocentric, intra-individual, randomised study involving 502 children using the results of nasopharyngeal aspirates as the gold standard. We will also evaluate the time required to take nasopharyngeal aspirates and saliva samples in order to examine any difficulties associated with the two sampling methods. Although the results of our study report few diagnostic errors, they would justify the use of saliva sampling in routine care to reduce stressful and painful factors, and thus contribute to the well-being of infants and children. Saliva sampling could improve acceptance by the child and those around him, avoiding a less negative experience while guaranteeing a reliable diagnosis of respiratory pathogens. This new technique should also encourage the active involvement of all those involved in care.",[28,431],"Virus Diseases in Children","2026-01-13",{"date":434,"type":41},"2026-01-20",{"date":117,"type":23},{"date":437,"type":23},"2030-07-01",{"name":439,"class":76},"Poitiers University Hospital",{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":446,"eligibilityCriteria":447,"healthyVolunteers":12,"sex":57,"minAge":448,"maxAge":449,"enrollmentInfo":450,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":452,"conditions":453,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":49},"100306407","impact-of-epileptic-discharge-on-the-structural-connectivity-of-the-developing-brain-100306407","NCT03268824","Impact of Epileptic Discharge on the Structural Connectivity of the Developing Brain","Impact of Epileptic Discharge on the Structural Connectivity of the Developing Brain: Combination of Intracerebral Stereotactic Electroencephalography Recording and Diffusion Tensor Imaging in Children With Drug-resistant Focal Epilepsy","EPITRACT","Inclusion Criteria:\n\n\\- Drug resistant focal epilepsy\n\nInclusion Criteria for control patients:\n\n\\- without drug resistant focal epilepsy\n\nExclusion Criteria:\n\n* Severe mental retardation (IQ \\\u003C 50)\n* Lack of French-language skills\n* Contraindications to MRI\n* Bi-hemispherical epilepsy or affecting multiple lobes\n\nExclusion Criteria for control patients:\n\n* Severe mental retardation (IQ \\\u003C 50)\n* Lack of French-language skills\n* Contraindications to MRI\n* Congenital pathology altering cerebral connectivity\n* Parenchymal brain lesions\n* Unilateral or bilateral blindness\n* Unilateral or bilateral deafness\n* Autistic disorders","18 Months","16 Years",{"count":451,"type":23},82,"Focal epilepsy is associated with widespread alterations in structural brain connectivity, often present at the disease onset and related to learning disabilities. Whether ongoing seizure activity contributes to network pathology is a matter of debate. This study intends to measure the impact of seizures on structural connectivity on a local and on a global level. In children examined with intracerebral electrodes to evaluate whether a surgical cure can be proposed, we combine intracerebral stereotactic electroencephalography (EEG) recordings with diffusion weighted imaging of white matter fibers. On the local level, the study will quantify the number of deficient connections in the seizure onset zone. On a global level, the study will compare the white matter fibers of the left and right hemisphere to probe whether physiological language lateralization is preserved.",[454,28,455],"Epilepsies, Focal","Drug Resistant Epilepsy","2025-12-30",{"date":458,"type":41},"2026-01-05",{"date":460,"type":41},"2017-12-19",{"date":462,"type":23},"2026-07",{"name":464,"class":465},"Fondation Ophtalmologique Adolphe de Rothschild","NETWORK",{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":470,"acronym":4,"eligibilityCriteria":471,"healthyVolunteers":12,"sex":57,"minAge":472,"maxAge":59,"enrollmentInfo":473,"targetDuration":4,"studyType":89,"phases":475,"briefSummary":476,"conditions":477,"keywords":479,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":4},"100617488","application-of-child-life-services-in-pediatric-skin-prick-test-100617488","NCT07319273","Application of Child Life Services in Pediatric Skin Prick Test","Inclusion Criteria:\n\n* Meet the indications for skin prick test (SPT)\n* Aged 1-18 years\n* Voluntarily agree to participate in the study and provide informed consent\n\nExclusion Criteria:\n\n* Meet the contraindications for SPT\n* Presence of psychiatric disorders or cognitive impairment\n* Severe dysfunction of vital organs such as the heart, brain, or kidneys","1 Year",{"count":474,"type":23},140,[163],"The goal of this clinical trial is to determine whether child life services can enhance the experiences of children and caregivers during skin prick testing. The main questions it aims to answer are:\n\n1. Can child life services alleviate children's pain and enhance procedural compliance?\n2. Can child life services reduce caregivers' anxiety and improve their satisfaction? Researchers will compare children who receive child life services with those who receive standard care to determine whether the intervention can optimize procedural experience and overall satisfaction.\n\nParticipants will receive either child life services or standard care during the skin prick test.",[478,28],"Hypersensitivity",[480,481,482,483,484],"child life services","skin prick test","pain","anxiety","pediatric nursing","2025-12-21",{"date":487,"type":41},"2026-01-06",{"date":489,"type":23},"2026-01",{"date":491,"type":23},"2026-12",{"name":179,"class":76},{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":497,"acronym":498,"eligibilityCriteria":499,"healthyVolunteers":12,"sex":57,"minAge":500,"maxAge":59,"enrollmentInfo":501,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":503,"conditions":504,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":516},"100612903","fasting-induced-hypoglycaemia-in-anaesthetised-paediatric-patients-100612903","NCT07259629","Fasting Induced Hypoglycaemia in Anaesthetised Paediatric Patients","FIGS","Inclusion Criteria:\n\n* All American Society of Anesthesiology score (ASA) 1 - 3 children aged 1 month to 18 years presenting for an elective procedure involving general anaesthesia during the defined study period\n* All elective cases, day cases will be included (patient's admitted the night before for bowel preparation prior to elective colonoscopy should also be included)\n* Planned expedited cases in ASA 1 \u002F 2 children should be included, for example nail bed repairs, lacerations, foreign body (in ear \u002F eye \u002F nose), simple fractures for manipulation under anesthesia \u002F k-wires\n* MRI, radiology and dental cases will be included provided the patient receives a general anaesthetic\n\nExclusion Criteria:\n\n* Children aged less than 1 month\n* Procedures performed under oral sedation or local anaesthesia only\n* ASA status 4 and 5\n* Children with any endocrine or metabolic condition or who have a fasting plan prior to general anaesthesia for glucose control:\n* Type 1 or 2 diabetes mellitus, medium chain acetyl Co-enzyme A, maple syrup urine disease, glycogen storage disease, galactosaemia, urea cycle defects, familial hypercholesterolaemia, congenital disorders of glycosylation, lysosomal storage disorders, organic acidaemias, mitochondrial disorders, adrenal gland disorders, adrenoleukodystrophy, growth disorders, lipid disorders, multiple endocrine neoplasia type 1 and 2, pituitary disorders.\n* Emergency and oncology procedures as these children will have different risk factors for hypoglycaemia\n* Anaesthetic involvement in critically ill children e.g. airway management in emergency department, pediatric intensive care unit\n* Children on glucose containing intravenous solutions or total parenteral nutrition pre-operatively\n* Children on systemic steroid treatment (oral \u002F intravenous). Children on inhalers \u002F topical steroids should be included","1 Month",{"count":502,"type":23},6580,"Fasting is a requirement to safely anesthetise patients referred for elective procedure, using the traditional 6\u002F4\u002F2 rule (6h for solid food or formula milk, 4h for breast milk and 2h for clear fluids), applied to all patients regardless of their age or weight. Reducing the aspiration risk however puts young children at higher risk of hypoglycemia due to the immaturity of their endocrine system and absence of metabolic reserves. The Association of Paediatric Anaesthetists of Great Britain and Ireland recommends that during day case surgery the majority of children may be given fluids without dextrose, provided blood glucose is monitored. Recent statements recommend continuing fluids until 1h before the procedure or even to give fluids when anesthetists sent for the patients. Hypoglycemia is rare in children above 2 years of age. Although the definition of hypoglycemia can differ, a threshold of 3.6mmol\u002Fl is often used given the potential neurological harm existing below this value. There is no consensus on the definition of hypoglycemia in children being fasted prior to general anesthesia, nor when nor how to treat it. Measurements are done for complex surgeries or patients deemed at risk according to the anesthetists. An audit was run in 2017 at the \" Evelina London Children's Hospital \", Guy's and St Thomas' National Health Service Foundation Trust, identifying 8% of children below 2 years of age as hypoglycemic. Recent review of our Incident Reporting Systems identified 3 cases, in otherwise fit and healthy children, referred for colonoscopy with initial hypoglycemia followed by rebound hypoglycemia after management. There is an urgent need to establish a clear definition of hypoglycemia and investigate risk factors in paediatric patients referred for elective procedures under general anesthesia.",[505,506,28],"Hypoglycemia; Iatrogenic","Anesthesia","2025-11-20",{"date":509,"type":41},"2025-12-02",{"date":511,"type":41},"2025-05-12",{"date":513,"type":23},"2027-01-12",{"name":515,"class":76},"Guy's and St Thomas' NHS Foundation Trust",3,{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":523,"eligibilityCriteria":524,"healthyVolunteers":12,"sex":57,"minAge":251,"maxAge":4,"enrollmentInfo":525,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":527,"conditions":528,"keywords":533,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":548},"100600818","complexity-in-health-education-and-social-support-for-children-and-young-people-with-life-limiting-conditions-100600818","NCT07102433","Complexity in Health, Education, and Social Support for Children and Young People With Life-limiting Conditions.","CHESS - Complexity and Outcomes in Health, Education, and Social Support Among Children and Young People With Life-limiting Conditions: Establishing a Multisectoral Collaboration and Conceptual Framework to Advance Evidence and Practice.","CHESS","Stage 1 - Interviews\n\nInclusion Criteria:\n\n* Children (5-17 years) with any life-limiting condition defined using the UK Together for Short Lives widely adopted 4 categories of life-limiting\u002Flife-threatening conditions among children.\n* Parents\u002Fcarers of children (0-17 years old) with a life-limiting conditions.\n* Bereaved parents of a child who had a life-limiting condition (at least 3 months since bereavement).\n* Healthcare professionals (medicine, nursing, allied health professionals), social care providers, education teaching and therapy staff with \\> 6 months experience of caring for children with life-limiting conditions.\n\nExclusion Criteria:\n\n* Children unable to communicate via an interview, using 'draw and talk' or play methods, Talking MatsTM, or via their parents.\n* Children that speak languages not supported by NHS translation services.\n* Any child or young person for whom the PI believes participation in the study may induce undue psychological distress.\n* Parents\u002Fcarers are unable to provide consent\u002Fassent to participate in interviews.\n* Parents\u002Fcarers that speak languages not supported by NHS translation services.\n* Parents who are recently bereaved (\\\u003C3 months).\n* Any parent\u002Fcarer for whom the PI believes participation in the study may induce undue psychological distress (e.g. parents of children who may be receiving end-of-life care).\n* Professionals with \\\u003C6 months experience of caring for children with life-limiting conditions.\n\nStage 2 - Workshops\n\nInclusion criteria:\n\n* Parents or carers of children with a life-limiting condition (0-17 years old).\n* Bereaved parents of a child who had a life-limiting condition (at least 3 months since bereavement).\n* Researchers working with or in the field of complexity in children with life-limiting conditions.\n* Professionals across child health, social care, and education with experience of working with children with life-limiting conditions for \\>6 months.\n\nExclusion criteria:\n\n* Professionals across child health, social care, and education with \\\u003C6 months of experience working with children with life-limiting conditions.\n* Parents, carers, or professionals that are unable to provide consent or assent.\n* Children with life-limiting\u002Flife-threatening conditions will not be included in the workshops\n* Parents who are recently bereaved (\\\u003C3 months) of a child who had a life-limiting condition.",{"count":526,"type":23},170,"Children and young people (CYP) with life-limiting conditions represent a growing population with complex care needs that span health, education, and social care systems. These children often have multiple diagnoses, rely on medical technologies, and experience prolonged trajectories of illness. Despite this, care remains fragmented, services are poorly integrated, and definitions of \"complexity\" are variable, inconsistent, and inadequately reflect the lived experience of families and the perspectives of professionals.\n\nThe CHESS (Complexity in Health, Education, and Social Support) study aims to develop a shared, evidence-informed understanding of \"complexity\" in the context of CYP with life-limiting conditions. The study will be delivered by a multi-disciplinary, multisectoral research team and is funded by a National Institute for Health and Care Research (NIHR) Programme Development Grant. This research will provide the foundational work to inform the design and implementation of a future NIHR Programme Grant focused on the development and testing of a child-centred, nationally applicable case mix classification system to support integrated multisector care and resource allocation.\n\nThis qualitative study involves two stages. Stage 1 consists of semi-structured interviews with (i) CYP aged 5-17 years with a life-limiting condition, (ii) parents\u002Fcarers (including bereaved parents and parents of children aged under 5 years), and (iii) professionals across healthcare, social care, and education sectors. These interviews aim to elicit stakeholder understandings of \"complexity,\" how it is experienced and enacted in care, and the implications for service access, coordination, and outcomes.\n\nStage 2 comprises a series of stakeholder workshops to review, refine, and synthesise findings from Stage 1 and a parallel realist review. Using consensus methods including the Nominal Group Technique, the workshops will co-develop a cross-sectoral conceptual definition of \"complexity\" and produce a logic model to guide integrated care delivery for this population.\n\nThe CHESS study seeks to address a critical evidence gap in how complexity is understood, measured, and supported across systems. By incorporating the voices of children, families, and professionals across sectors, this study will generate new conceptual clarity, build a foundation for improved outcomes, and contribute directly to the national agenda on equity, quality, and integration in paediatric palliative and complex care.",[529,530,28,531,532],"Complex Care","Medical Complexity","Life-limiting Illness","Life-threatening Illness",[534,535,536,537,538],"Medical complexity","Pediatric palliative care","Life-limiting conditions","Life-threatening conditions","Children and young people","2025-11-13",{"date":541,"type":41},"2025-11-14",{"date":543,"type":23},"2025-12-01",{"date":545,"type":23},"2026-07-31",{"name":547,"class":76},"King's College London",5,{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":555,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":57,"minAge":557,"maxAge":558,"enrollmentInfo":559,"targetDuration":472,"studyType":24,"phases":4,"briefSummary":561,"conditions":562,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":49},"100606970","turkish-version-of-the-brief-hammersmith-infant-neurological-examination-hine-100606970","NCT07182474","Turkish Version of the BRIEF-Hammersmith Infant Neurological Examination (HINE)","Turkish Version of the BRIEF-Hammersmith Infant Neurological Examination (HINE) With High-Risk of Infants: A Study of Validity and Reliability","BRIEF-HINE","Inclusion Criteria:\n\n* Infants with high risk of CP: Periventricular hemorrhage, intracranial hemorrhage grade 2, 3, 4, cystic PVL, stage 3 hypoxic ischemic encephalopathy, neonatal bilirubin encephalopathy (kernicterus), perinatal stroke, perinatal asphyxia, respiratory distress syndrome (RDS), bronchopulmonary dysplasia (BPD) and infants receiving long-term O₂ support, sepsis due to gram-negative bacteria, necrotizing enterocolitis (NEC), infantile apnea, those with a low 5-minute Apgar score (3 and below), those diagnosed with intrauterine growth retardation, multiple births (twins, triplets), preterm infants with retinopathy of prematurity (ROP), infants with prolonged severe hypoglycemia and hypocalcemia, (small for gestational age (SGA), less than the 3rd percentile) or large for gestational age (large for gestational age (LGA), less than the 97th percentile). (large) babies, babies receiving mechanical ventilation for more than 24 hours, babies born at less than 32 weeks of gestation and weighing less than 1500 grams.\n\nExclusion Criteria:\n\n* Infants with any known orthopedic, systemic disease or neurological diagnosis other than CP","3 Months","12 Months",{"count":560,"type":23},120,"The American Academy of Pediatrics defines high-risk infants as those with preterm birth, special health care needs, family risk factors, and those at risk of early death. Factors such as premature birth, perinatal asphyxia, hypoxic-ischemic encephalopathy (HIE), periventricular leukomalacia (PVL), intraventricular hemorrhage (IVH), chronic lung disease, seizures, meningitis, hyperbilirubinemia, twin\u002Ftriplet pregnancy, and intrauterine growth restriction are risk factors that can result in morbidity and mortality in infants. Regular neurological examinations and neuromotor tests are necessary for at-risk infants to identify developmental problems early and to initiate early intervention programs.In developing countries, regular follow-up and early rehabilitation of at-risk infants are not successfully implemented. 5,6 The lengthy test batteries and busy clinics are among the most significant reasons. Therefore, the development and dissemination of shorter, valid, and reliable tests is of great importance. The Hammersmith Neonatal Neurological Examination (HINE), one of the gold standard methods, consists of 26 items and takes 15-20 minutes to administer.Due to the number of items and the duration, it is not frequently used routinely. In response to this clinical need, the HINE short scale was developed in 2024.The aim of the study is to have a Turkish version of the Abstract-HINE test in Turkey and to study its validity and reliability in high-risk infants.",[28,563,564],"Neurological Abnormality","Neurodevelopment Outcome","2025-09-18",{"date":567,"type":41},"2025-09-19",{"date":569,"type":41},"2025-08-22",{"date":571,"type":23},"2026-10-30",{"name":573,"class":76},"Kahramanmaras Sutcu Imam University",{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":580,"eligibilityCriteria":581,"healthyVolunteers":12,"sex":57,"minAge":4,"maxAge":59,"enrollmentInfo":582,"targetDuration":4,"studyType":89,"phases":584,"briefSummary":585,"conditions":586,"keywords":591,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":302},"100548990","hospital-to-home-transitional-care-interventions-h2h-tci-childrenyouth-with-special-health-care-needs-cyshcn-100548990","NCT06428175","Hospital-to-Home Transitional Care Interventions (H2H-TCI) Children\u002FYouth With Special Health Care Needs (CYSHCN)","Hospital-to-Home Care Coordination for Children and Youth With Special Health Care Needs","H2H-CYSHCN","Inclusion Criteria:\n\n* For this study, eligible children\u002Fyouth with special health care needs (CYSHCN) and adult parent\u002Fcaregiver dyads will be those who meet the following inclusion criteria:\n\n  1. Child is a CYSHCN, defined as having seen two or more distinct specialty areas for outpatient visits during the 12 months prior to index hospitalization admission date\n  2. Age of hospitalized child is under 18 years old\n  3. Child hospitalized on a general pediatrics inpatient service line at participating site\n  4. Adult parent\u002Fcaregiver for the child is 18 years or older\n\nExclusion Criteria:\n\n* Child exclusion criteria:\n\n  1. Child will be discharged to any location besides home (e.g., long-term care or residential facility, skilled nursing facility, inpatient acute rehabilitation, psychiatric facility)\n  2. Child is a ward of the state or has an ongoing social services investigation\n  3. Child is already receiving transitional care, intensive longitudinal care coordination (e.g., organ\u002Fdisease-specific clinical program, clinical division within the same institution as the hospital \\[e.g., Children's Complex Care Program at UNC; Complex Care Service at Duke\\]), and\u002For longitudinal population health care coordination as part of a bundled alternative payment care model.\n* Parent\u002Fcaregiver exclusion criteria include:\n\n  1. Age less than 18 years old\n  2. Diminished capacity to provide consent\u002Fparticipate\n  3. Primary language for parent\u002Fcaregiver is any language besides English or Spanish",{"count":583,"type":23},480,[163],"Aim 1: Compare the effectiveness of focused dose vs extended dose hospital-to-home Transitional Care Interventions (H2H-TCI) on health service use and parent-reported confidence for hospitalized CYSHCN. Aim 2: Compare the effectiveness of focused and extended dose H2H-TCI among vulnerable CYSHCN subgroups. Hypothesis: Both H2H-TCI arms will improve primary outcomes more for CYSHCN with higher versus lower clinical complexity; while extended H2H-TCI will better mitigate racial\u002Fethnic outcome disparities than focused H2H-TCI. Aim 3: Evaluate implementation context, processes, and mechanisms via a multi-phase mixed methods study design.",[587,28,588,589,590],"Health Care","Transitional Care","Comparative Effectiveness","Family Engagement",[592,593,594,595],"Special Needs","Hospital to Home Care","Children and Youth with Special Health Care Needs","Randomized Trial","2025-09-05",{"date":598,"type":41},"2025-09-11",{"date":600,"type":41},"2025-08-28",{"date":602,"type":23},"2029-02",{"name":604,"class":76},"Duke University",{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":57,"minAge":612,"maxAge":86,"enrollmentInfo":613,"targetDuration":615,"studyType":24,"phases":4,"briefSummary":616,"conditions":617,"keywords":620,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":624,"lastUpdatePostDateStruct":625,"startDateStruct":627,"completionDateStruct":629,"leadSponsor":630,"locationsCount":302},"100598343","pediatric-intensive-care-transport-registry-100598343","NCT07070258","Pediatric Intensive Care Transport Registry","PIT Registry","Inclusion Criteria:\n\n* Critically ill children aged at least 27 days and a corrected gestational age of over 41 weeks AND\n* Maximum age of 17 years AND\n* Interhospital transport AND\n* Critical care transport by a dedicated critical care transport team using an intensive care ambulance (Type C vehicle) or an air ambulance OR\n* The transport was accompanied by a specialist in intensive care or emergency medicine. OR\n* The in-hospital destination of the transport is a critical care area, such as an intensive care unit, a trauma room, a resuscitation area, an operating theatre, an emergency imaging procedure or an emergency intervention.","27 Days",{"count":614,"type":23},1000,"1 Day","The aim is to establish a nationwide registry for pediatric intensive care transports in Germany. The project aims to describe and analyse the need for, and current practice of, specialised transports. These data could then be used for future demand planning.",[618,619,28],"Critical Care Medicine","Transportation of Patients",[621,622,234,623],"intensive care transport","critical care transport","registry","2025-07-16",{"date":626,"type":41},"2025-07-20",{"date":628,"type":41},"2024-11-25",{"date":269,"type":23},{"name":631,"class":76},"Philipps University Marburg",{"id":633,"slug":634,"hasResults":12,"nctId":635,"briefTitle":636,"officialTitle":636,"acronym":4,"eligibilityCriteria":637,"healthyVolunteers":12,"sex":57,"minAge":638,"maxAge":639,"enrollmentInfo":640,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":642,"conditions":643,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":649,"lastUpdatePostDateStruct":650,"startDateStruct":651,"completionDateStruct":653,"leadSponsor":655,"locationsCount":49},"100598166","prevalence-of-functional-lower-urinary-tract-voiding-dysfunction-in-school-aged-children-100598166","NCT07067957","Prevalence of Functional Lower Urinary Tract Voiding Dysfunction in School-Aged Children","Inclusion Criteria:\n\n* Children aged 4-14 years old in our locality.\n\nExclusion Criteria:\n\n* Children with known anatomical anomalies of urinary tract\n* Children with known neurological anomalies (spinal dysraphism, multiple sclerosis, lumbar or spinal neuritis……… etc)\n* Children with history of back or lower urinary tract trauma\n* Parents who refuse participation","4 Years","14 Years",{"count":641,"type":23},500,"The aim of this study is to investigate the prevalence of voiding disorders and the related risk factors for the primary school-age children in El Ghrbia Government",[644,645,646,647,28,648],"Voiding Dysfunction","Urinary Incontinence","Urination Disorders","Lower Urinary Tract Symptoms","Constipation","2025-07-06",{"date":624,"type":41},{"date":652,"type":23},"2025-07-10",{"date":654,"type":23},"2025-11-30",{"name":656,"class":76},"Tanta University",{"id":658,"slug":659,"hasResults":12,"nctId":660,"briefTitle":661,"officialTitle":662,"acronym":663,"eligibilityCriteria":664,"healthyVolunteers":12,"sex":57,"minAge":4,"maxAge":665,"enrollmentInfo":666,"targetDuration":4,"studyType":89,"phases":668,"briefSummary":669,"conditions":670,"keywords":672,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":674,"lastUpdatePostDateStruct":675,"startDateStruct":677,"completionDateStruct":679,"leadSponsor":680,"locationsCount":49},"100476207","improving-nighttime-access-to-care-and-treatment-part-4-haiti-100476207","NCT05480930","Improving Nighttime Access to Care and Treatment; Part 4-Haiti","Novel Approach to Improve Patient Care and Diarrheal Disease Research Using Mobile Technology in Haiti","INACT4-H","Inclusion criteria for child, parent\u002Fguardian participants:\n\n* Children 10 years of age or younger with an acute illness\n* Parent\u002Fguardian contacts the TMDS in regards to the illness during hours of operation\n* Parental\u002Fguardian agreement to a waiver of documentation of consent when contact is by phone only OR written consent\u002Fassent at the household from the parent\u002Fguardian and child (7yrs and older) for participants who receive a household visit.\n\nExclusion criteria for child, parent\u002Fguardian participants:\n\n* No consent","10 Years",{"count":667,"type":23},7124,[163],"Children in resource-limited settings who develop illness at night are often isolated from care, resulting in progression to an emergency. A telemedicine and medication delivery service (TMDS) is a viable healthcare delivery option to bridge the gap in nighttime care. This interrupted time series study (pre\u002Fpost) will evaluate a digital clinical decision-support (dCDS) tool. The objective is to assess if the tool is associated with an improvement in guideline adherence by TMDS providers.",[671,28],"Telemedicine",[673],"digital clinical decision support","2025-06-26",{"date":676,"type":41},"2025-06-30",{"date":678,"type":41},"2022-09-27",{"date":217,"type":23},{"name":681,"class":76},"University of Florida",{"id":683,"slug":684,"hasResults":12,"nctId":685,"briefTitle":686,"officialTitle":687,"acronym":688,"eligibilityCriteria":689,"healthyVolunteers":12,"sex":57,"minAge":690,"maxAge":691,"enrollmentInfo":692,"targetDuration":4,"studyType":89,"phases":694,"briefSummary":695,"conditions":696,"keywords":702,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":706,"lastUpdatePostDateStruct":707,"startDateStruct":709,"completionDateStruct":711,"leadSponsor":712,"locationsCount":714},"100567641","novel-tools-to-improve-management-of-paediatric-community-acquired-pneumonia---toolcap-100567641","NCT06670833","Novel Tools to Improve Management of Paediatric Community-Acquired Pneumonia - ToolCAP","ToolCAP: Novel Tools to Improve Management of Paediatric Community-Acquired Pneumonia","ToolCAP","Inclusion Criteria:\n\n* Cough OR Difficulty Breathing AND,\n* One of the below:\n\nFast breathing (tachypnoea) \\> 50\u002Fminute (2-12 months) \\> 40\u002Fminute (1-\\\u003C5 years) \\> 25\u002Fminute (5-12 years) OR Lower chest wall indrawing\n\nExclusion Criteria:\n\n* Presenting for repeat visit\u002Ffollow-up of a treated lower respiratory tract infection (index illness \u002F non-acute) or enrolled in the study within the preceding 28 days.\n* Received antibiotic treatment for more than 48 hours at the time of enrolment.\n* WHO IMCI danger signs (inability to drink\u002Fbreastfeed, vomiting everything, convulsions with this illness, lethargy\u002Funconscious).\n* Presence of jaundice.\n* Hypoxaemia with oxygen saturation (SpO2) \\\u003C88%\n* Oxygen saturation (SpO2) \\\u003C90% (or country-specific \u002F altitude-adjusted thresholds) i) With signs of severe respiratory distress (such as nasal flaring, grunting, etc.) OR ii) In children \\\u003C 6 months\n* Requiring non-invasive ventilatory support (i.e., high-flow, bilevel positive airway pressure (BiPAP) and continuous positive airway pressure (CPAP))\n* Underlying disease associated with increased risk of severe pneumonia or pneumonia of unusual aetiology (e.g., WHO acute malnutrition requiring antibiotics as per local guidelines, severe immunodeficiency)\n* HIV positive participant that is either i) less than 12 months old; OR ii) requires admission for this illness; OR iii) known to be uncontrolled on treatment (with a documented VL \\>1000c\u002Fml in the previous 6 months)\n* Caregiver unavailable at the time of enrolment, or unwilling, to provide informed consent.","60 Days","12 Years",{"count":693,"type":23},3500,[163],"The ToolCAP study aims to see if using ultrasound to look at the lungs when children have symptoms of a lung infection will safely allow doctors to improve how they treat those infections. The study will also look at if it's possible to improve how doctors decide which children need antibiotics.\n\n* Lung infections are the most common reason for children to go to the clinic\u002Fhospital.\n* Doctors usually give an antibiotic to every child with a lung infection.\n* Lung infections can be caused by 2 different types of germs - bacteria or viruses.\n* Antibiotics only work against bacteria and not against viruses. Lung infections caused by viruses don't need antibiotics as the body fights them by itself.\n* Lots of research now shows that only 1 in 4 children with a lung infection actually needs an antibiotic, as the rest only have a viral infection causing the symptoms.\n* This means that 3 in 4 children get an antibiotic when they don't need it.\n* Taking too many antibiotics can cause problems for children as it can cause diseases like diabetes or asthma.\n* Nowadays, due to too many people using too many antibiotics, experts are starting to worry that bacteria are starting to become resistant (stronger than the antibiotic).\n* Ultrasound of the lungs appears to be a way of safely looking at the lungs to see if there is an infection and may help doctors better decide who needs an antibiotic.\n\nThis study includes children aged 2 months-12 years who come to the hospital with a lung infection. Children who are very unwell or who have already had 2 days of antibiotic treatment will not be allowed to be in the study.",[697,698,699,28,700,701],"Pneumonia","Pneumonia Childhood","Pneumonia - Bacterial","LRTI","IMCI Guidelines",[703,704,705],"Lung ultrasound (LUS)","Lung auscultation","Pediatric pneumonia","2025-06-17",{"date":708,"type":41},"2025-06-18",{"date":710,"type":41},"2025-04-04",{"date":491,"type":23},{"name":713,"class":76},"University of Bern",9]